Friday morning and afternoon, officials conducted a deliberate — and sometimes difficult — serious mental illness hearing for ...
Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...
CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...
Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...
Interesting Engineering on MSN6h
US approves first nasal spray for major depressive disorder, PTSD conditionsJohnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...
The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
Major depressive disorder (MDD) is a chronic and recurrent mental condition leading to huge impacts on direct and indirect personal and public medical costs. To overcome such a serious mental ...
Hosted on MSN1d
FDA Clears Spravato For Monotherapy Depression TreatmentsThe Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...
Existing drugs for manic depression - such as loxapine, promazine and haloperidol - can cause weight gain and a feeling of tiredness and lethargy. They have also been inconsistent at preventing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback